Heritage Investors Management Corp Sells 7,620 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Heritage Investors Management Corp lessened its stake in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 6.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 106,629 shares of the company’s stock after selling 7,620 shares during the quarter. Heritage Investors Management Corp’s holdings in Takeda Pharmaceutical were worth $1,412,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of TAK. Versant Capital Management Inc bought a new stake in Takeda Pharmaceutical during the fourth quarter worth $26,000. Wilmington Savings Fund Society FSB bought a new stake in Takeda Pharmaceutical during the third quarter worth $40,000. BNP Paribas Financial Markets lifted its holdings in Takeda Pharmaceutical by 416.0% during the third quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company’s stock worth $46,000 after acquiring an additional 2,596 shares during the period. Smithfield Trust Co lifted its holdings in Takeda Pharmaceutical by 76.9% during the third quarter. Smithfield Trust Co now owns 3,428 shares of the company’s stock worth $49,000 after acquiring an additional 1,490 shares during the period. Finally, Erste Asset Management GmbH bought a new stake in Takeda Pharmaceutical during the third quarter worth $52,000. Institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Performance

Shares of Takeda Pharmaceutical stock opened at $14.35 on Friday. The firm has a market capitalization of $45.64 billion, a P/E ratio of 35.86, a price-to-earnings-growth ratio of 0.24 and a beta of 0.51. The business’s fifty day simple moving average is $13.38 and its 200 day simple moving average is $13.89. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63. Takeda Pharmaceutical Company Limited has a 12 month low of $12.57 and a 12 month high of $15.08.

Takeda Pharmaceutical (NYSE:TAK) last issued its earnings results on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. As a group, analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.